Dr Yokoyama is the author of Clofibric Acid, a Peroxisome Proliferator-activated Receptor Alpha Ligand, Enhances a Suppressive Effect of Cis-diaminedichloroplatinum on Proliferation of Ovarian Carcinoma Cells which was recently published in Clinical Medicine Insights: Oncology.
The Editor in Chief of Clinical Medicine Insights: Oncology recently issued a
call for papers.
Please describe your experience with Libertas Academica:
I found that the quality of the review was high and the review and publication process was very well-ordered. All readers can easily access the articles and I believe that they feel satisfied with excellent works in the articles.
What is the primary focus of your research?
Development of new therapeutic strategy for epithelial ovarian cancer focusing on anti-angiogenesis and induction of apoptosis and development of new medicine capable of inducing anti-angiogenesis and apoptosis.
What are the most exciting developments arising from current research in your area?
Photodynamic therapy using a methyl ester of 5-aminolevulinic acid was effect on inhibition of ovarian cancer growth.
Who are your main collaborators? Please describe your work with them.
Dr Shigeki Tsuchida. Clofibric Acid, a Peroxisome Proliferator-Activated Receptor α Ligand Inhibits Growth of Human Ovarian Cancer.
How did you come to be working in your research area?
My theme of doctorate course was "Identification of the protein induced in rat liver by clofibrate administration and its changes during hepatocarcinogenesis". Then, I became a gynecologic oncologist and have continued the research for chemoresistance and biology of ovarian cancer.
What do you think about the development of open access publishing? What motivated you to do so?
It is very significant and open access publishing can encourage young scientists to submit their research results.
What articles and/or books have you published recently?
- Efficacy of a methyl ester of 5-aminolevulinic acid in photodynamic therapy for ovarian cancers . J Cancer Res Clin Oncol in press Endostatin inhibits xenografted human ovarian cancer growth. Cancer Therapy 2009; 7: 347-353.
- Two cases of ovarian cancer at an early stage incidentally detected using transvaginal ultrasonography in screening: Importance of interval for ovarian cancer screening and selection of population with a high risk of ovarian cancer. Eur J Gynaecol Oncol 2009; 30: 208-210.
- A phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit Study. Oncol Rep 2008; 19: 1551-1556.
Further information:
share on
Facebook Google+ Twitter
Pinterest Tumblr YouTube